4.3 Article

Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease - a population-based database study

期刊

CLINICAL RESPIRATORY JOURNAL
卷 4, 期 1, 页码 22-29

出版社

WILEY
DOI: 10.1111/j.1752-699X.2009.00138.x

关键词

bone density conservation agents; glucocorticoids; osteoporosis; pulmonary disease; chronic obstructive

资金

  1. MSD

向作者/读者索取更多资源

Introduction: A common extrapulmonary effect to chronic obstructive pulmonary disease (COPD) is osteoporosis. Objectives: To characterise the diagnostic activity regarding osteoporosis [i.e. the use of dual-energy X-ray absorptiometry (DXA)] and the pattern of applied pharmacological intervention to prevent fractures in COPD patients in relation to the use of prednisolone. Methods: This study was a register study covering the residents of the Danish County of Funen linking data from Odense Pharmacoepidemiologic Database (OPED), a DXA-database and Funen Patient Administrative System, a database with data on hospitals admissions. OPED has complete capture of fulfilled prescriptions. We identified 1909 COPD patients admitted with a main diagnosis of COPD. Using OPED we extracted prescriptions for prednisolone and antiresorptive medicine from these COPD patients for the year 2004. Results: COPD patients who had filled a prescription for prednisolone (P-COPD) were DXA-scanned more frequently (17%) than those who had not (non-P-COPD) (9%) and were prescribed antiresorptive medicine more often (27%) than non-P-COPD (16%). In both groups 94% were either osteopenic or osteoporotic. Logistic regression models predicted that DXA-scans were offered to women, to the young, to the recipients of high systemic steroid doses and to those with frequent admission for COPD. Given an osteoporosis diagnosis, treatment was offered to those with high steroid doses and those with frequent admissions for COPD. Conclusion: DXA are underutilised compared with the high frequency of osteoporosis or osteopenia in DXA-scanned hospitalised COPD patients, especially in elderly. Guidelines concerning screening, prevention and treatment of osteoporosis in COPD patients with or without glucocorticoid treatment are needed. Please cite this paper as: Madsen H, Brixen K and Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease - a population-based database study. The Clinical Respiratory Journal 2009; DOI:10.1111/j.1752-699X.2009.00138.x.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Public, Environmental & Occupational Health

RE: Gout and sodium-glucose cotransporter-2 inhibitors

Lars Christian Lund, Mikkel Hojlund, Daniel Pilsgaard Henriksen, Jesper Hallas, Kasper Bruun Kristensen

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2022)

Article Pharmacology & Pharmacy

Lithium and the risk of chronic kidney disease: A population-based case-control study

Mikkel Hojlund, Jane Sterndorff Winkel, Mads Nybo, Jesper Hallas, Daniel Pilsgaard Henriksen, Per Damkier

Summary: The use of lithium, especially long-term, is associated with an increased risk of chronic kidney disease (CKD). However, the extent to which detection bias and confounding by indication contribute to this association remains unclear.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2022)

Article Cardiac & Cardiovascular Systems

Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study

Joris J. Komen, Anton Pottegard, Aukje K. Mantel-Teeuwisse, Tomas Forslund, Paul Hjemdahl, Bjorn Wettermark, Jesper Hallas, Morten Olesen, Marion Bennie, Tanja Mueller, Raymond Carragher, Oystein Karlstad, Lars J. Kjerpeseth, Olaf H. Klungel

Summary: Observational data suggests that NOAC treatment may have a positive net clinical benefit compared with no treatment or VKA treatment in low stroke risk patients.

EUROPEAN HEART JOURNAL (2022)

Article Pharmacology & Pharmacy

Association between gabapentinoids and oedema treated with loop diuretics: A pooled sequence symmetry analysis from the USA and Denmark

Scott Martin Vouri, Earl J. Morris, Grace Hsin-Min Wang, Alyaa Hashim Jaber Bilal, Jesper Hallas, Daniel Pilsgaard Henriksen

Summary: This study used large administrative health care databases to assess the prescribing cascade of gabapentinoids, edema, and loop diuretics in two countries. Evidence of this cascade was found, indicating a potential overuse of loop diuretics in patients using gabapentinoids.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Article Psychiatry

Impact of low-dose quetiapine-use on glycosylated hemoglobin, triglyceride and cholesterol levels

Mikkel Hojlund, Henrik Stovring, Kjeld Andersen, Christoph U. Correll, Jesper Hallas

Summary: The study investigated the association between low-dose off-label quetiapine and changes in metabolic parameters. The results showed that low-dose quetiapine was associated with increased triglycerides and decreased high-density lipoprotein in all subjects, as well as increased HbA1c, total cholesterol, and low-density lipoprotein among those with normal baseline values.

ACTA PSYCHIATRICA SCANDINAVICA (2023)

Article Pharmacology & Pharmacy

Use of benzodiazepines and benzodiazepine-related drugs in the Nordic countries between 2000 and 2020

Mikkel Hojlund, Larus S. Gudmundsson, Jacob H. Andersen, Leena K. Saastamoinen, Helga Zoega, Svetlana O. Skurtveit, Jonas W. Wastesson, Jesper Hallas, Anton Pottegard

Summary: The use of benzodiazepines and related drugs has decreased in the Nordic countries from 2004 to 2020, with significant differences between countries. Despite warnings, benzodiazepines are still commonly used in the older population.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2023)

Letter Neurosciences

Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events

Mikkel Hojlund, Kjeld Andersen, Martin T. Ernst, Christoph U. Correll, Jesper Hallas

ACTA NEUROPSYCHIATRICA (2023)

Article Endocrinology & Metabolism

Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis

Lars Christian Lund, Patricia Hjorslev Jensen, Anton Pottegard, Morten Andersen, Nicole Pratt, Jesper Hallas

Summary: Using Danish nationwide health registries, researchers identified 70 drug-diabetes associations, of which 27 were previously unknown. These findings are important for understanding the drugs that can cause diabetes.

DIABETES OBESITY & METABOLISM (2023)

Letter Public, Environmental & Occupational Health

Recommendations on the calculation of confidence intervals for sequence symmetry analyses

Lars Christian Lund, Jesper Hallas

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Otorhinolaryngology

Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273: A Danish Population-Based Cohort Study

Per Damkier, Brian Cleary, Jesper Hallas, Jesper H. H. Schmidt, Louise Ladebo, Peter B. B. Jensen, Lars Christian Lund

Summary: This study compared the occurrence of sudden sensorineural hearing loss after immunization with BNT162b2 (Comirnaty; Pfizer BioNTech) or mRNA-1273 (Spikevax; Moderna) vaccines to unvaccinated individuals. The results showed that there was no association between these vaccines and the occurrence of sudden sensorineural hearing loss, but there was a slightly increased risk of receiving moderate to high-dose prednisolone treatment after visiting an ear-nose-throat specialist.

OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2023)

Article Health Care Sciences & Services

Harnessing patient complaints to systematically monitoring healthcare concerns through disproportionality analysis

Soren Bie Bogh, Soren Fryd Birkeland, Sebrina Maj-Britt Hansen, Olga Alexandrovna Tchijevitch, Jesper Hallas, Lars Morso

Summary: Analyzing patient complaints can help identify potential areas for improvement in hospitals, including quality, safety, institutional, and environmental issues. Disproportionality analysis of complaints is a valuable tool for systematically monitoring patient concerns.

INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE (2023)

Article Public, Environmental & Occupational Health

A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea

Martin Torp Rahbek, Lars Christian Lund, Jesper Hallas

Summary: Using observational data, we found that liraglutide, a GLP1-RA, may have a collateral drug benefit of reducing bile acid diarrhea.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Letter Public, Environmental & Occupational Health

Trend adjustment of the sequence difference when performing sequence symmetry analyses

Martin Torp Rahbek, Jesper Hallas, Lars Christian Lund

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Public, Environmental & Occupational Health

Application of the waiting time distribution in a nationwide screening of real-world dermatology drug utilization for aberrant use patterns

Thomas Delvin, Anette Bygum, Lars Christian Lund, Jacob Harbo Andersen, Jesper Hallas

Summary: This study applied the waiting time distribution (WTD) method to screen for aberrant drug use in dermatology drugs in Denmark. The findings showed that most drugs are used as intended, with few unexpected use patterns identified. Further investigation and follow-up are needed for the identified signals of inappropriate use.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Cardiac & Cardiovascular Systems

Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study

Morten Schmidt, Jesper Hallas, Martin Thomsen Ernst, Anton Pottegard

Summary: This study explored whether the cardiovascular risks associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) differ between patients continuing and initiating use after first-time myocardial infarction (MI) or heart failure (HF). The results showed that initiators of NSAIDs were more susceptible to adverse cardiovascular outcomes than continuing users.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

暂无数据